REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) Director Kenneth T. Mills sold 20,602 shares of the firm’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company’s stock, valued at $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

REGENXBIO Stock Up 1.8%

NASDAQ:RGNX opened at $8.33 on Thursday. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.85. The stock’s fifty day simple moving average is $7.43 and its 200-day simple moving average is $7.99. The firm has a market capitalization of $417.47 million, a P/E ratio of -1.66 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after buying an additional 67,948 shares during the period. Wells Fargo & Company MN grew its holdings in shares of REGENXBIO by 34.0% during the fourth quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company’s stock worth $374,000 after buying an additional 12,285 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of REGENXBIO during the fourth quarter worth about $568,000. Institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

RGNX has been the topic of several research analyst reports. The Goldman Sachs Group decreased their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Morgan Stanley raised their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. Finally, HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.